I usually do not care much about Motley but they have a good point. It's a case of acquire or being acquired at this point. Tabalumab does not look that promising, diabetese drugs are tough and not that exciting, Baricitinib looks good for RA (Xeljanz mechanism) and in phase 2 for psoriasis, actually INCY could be a nice addition with a onc product on the market, and a JAkinase pipeline. wonder why they have not already jump on this. Any thoughts?